Signaling-specific inhibition of the CB

Animals Mice Cannabis Double-Blind Method Dronabinol / adverse effects Hallucinogens / therapeutic use Marijuana Abuse Randomized Controlled Trials as Topic Substance Withdrawal Syndrome / drug therapy

Journal

Nature medicine

ISSN: 1546-170X

Titre abrégé: Nat Med

Pays: United States

ID NLM: 9502015

Informations de publication

Date de publication:
Jun 2023

Historique:

received: 10 11 2022

accepted: 01 05 2023

medline: 26 6 2023

pubmed: 9 6 2023

entrez: 8 6 2023

Statut: ppublish

Résumé

Cannabis use disorder (CUD) is widespread, and there is no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB

Identifiants

DOI: 10.1038/s41591-023-02381-w PMID: 37291212 PMC: PMC10287566

pubmed: 37291212

doi: 10.1038/s41591-023-02381-w

pii: 10.1038/s41591-023-02381-w

pmc: PMC10287566

doi:

Substances chimiques

Dronabinol 7J8897W37S

Hallucinogens 0

Banques de données

ClinicalTrials.gov

['NCT03443895', 'NCT03717272', 'NCT03325595']

Types de publication

Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

Pagination

1487-1499

Subventions

Organisme : NIDA NIH HHS

ID : R01 DA038875

Pays : United States

Organisme : NIDA NIH HHS

ID : U54 DA037842

Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Références

Hasin, D. S. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology 43, 195–212 (2018).

doi: 10.1038/npp.2017.198 pubmed: 28853439

Substance Abuse and Mental Health Services Administration (SAMSHA). Key substance use and mental health indicators in the United States: results from the 2020 national survey on drug use and health (HHS publication no. PEP21-07-01-003, SAMSHA). https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf ) (2021).

Substance Abuse and Mental Health Services Administration (SAMSHA). Treatment Episode Data Set (TEDS): 2005–2015 national admissions to substance abuse treatment services (HHS publication no. (SMA) 17-5037, SAMSHA). https://www.samhsa.gov/data/sites/default/files/2015_Treatment_Episode_Data_Set_National/2015_Treatment_Episode_Data_Set_National.pdf (2017).

McLellan, A. T., Koob, G. F. & Volkow, N. D. Preaddiction—a missing concept for treating substance use disorders. JAMA Psychiatry 79, 749–751 (2022).

doi: 10.1001/jamapsychiatry.2022.1652 pubmed: 35793096

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th edn (American Psychiatric Association, 2013).

doi: 10.1176/appi.books.9780890425596

Brezing, C. A. & Levin, F. R. The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology 43, 173–194 (2018).

doi: 10.1038/npp.2017.212 pubmed: 28875989

Connor, J. P. et al. Cannabis use and cannabis use disorder. Nat. Rev. Dis. Prim. 7, 16 (2021).

doi: 10.1038/s41572-021-00247-4 pubmed: 33627670

Manning, J. J., Green, H. M., Glass, M. & Finlay, D. B. Pharmacological selection of cannabinoid receptor effectors: signalling, allosteric modulation and bias. Neuropharmacology 193, 108611 (2021).

doi: 10.1016/j.neuropharm.2021.108611 pubmed: 34000272

Glass, M., Faull, R. L. M. & Dragunow, M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77, 299–318 (1997).

doi: 10.1016/S0306-4522(96)00428-9 pubmed: 9472392

Piazza, P. V., Cota, D. & Marsicano, G. The CB1 receptor as the cornerstone of exostasis. Neuron 93, 1252–1274 (2017).

doi: 10.1016/j.neuron.2017.02.002 pubmed: 28334603

Vallée, M. et al. Pregnenolone can protect the brain from cannabis intoxication. Science 343, 94–98 (2014).

doi: 10.1126/science.1243985 pubmed: 24385629 pmcid: 4057431

Frau, R. et al. Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone. Nat. Neurosci. 22, 1975–1985 (2019).

doi: 10.1038/s41593-019-0512-2 pubmed: 31611707 pmcid: 6884689

Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H. & Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370, 1706–1713 (2007).

doi: 10.1016/S0140-6736(07)61721-8 pubmed: 18022033

Cook, S. A., Lowe, J. A. & Martin, B. R. CB

pubmed: 9618417

Vallée, M. Neurosteroids and potential therapeutics: focus on pregnenolone. J. Steroid Biochem. Mol. Biol. 160, 78–87 (2016).

doi: 10.1016/j.jsbmb.2015.09.030 pubmed: 26433186

Spanagel, R. Animal models of addiction. Dialogues Clin. Neurosci. 19, 247–258 (2017).

doi: 10.31887/DCNS.2017.19.3/rspanagel pubmed: 29302222 pmcid: 5741108

Venniro, M., Caprioli, D. & Shaham, Y. Animal models of drug relapse and craving: from drug priming-induced reinstatement to incubation of craving after voluntary abstinence. Prog. Brain Res. 224, 25–52 (2016).

doi: 10.1016/bs.pbr.2015.08.004 pubmed: 26822352

Busquets-Garcia, A. et al. Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice. Mol. Psychiatry 22, 1594–1603 (2017).

doi: 10.1038/mp.2017.4 pubmed: 28220044 pmcid: 5447368

Khan, M., Pace, L., Truong, A., Gordon, M. & Moukaddam, N. Catatonia secondary to synthetic cannabinoid use in two patients with no previous psychosis. Am. J. Addict. 25, 25–27 (2016).

doi: 10.1111/ajad.12318 pubmed: 26781357

Di Chiara, G. & Bassareo, V. Reward system and addiction: what dopamine does and doesn’t do. Curr. Opin. Pharmacol. 7, 69–76 (2007).

doi: 10.1016/j.coph.2007.02.001 pubmed: 17174602

Wenzel, J. M. & Cheer, J. F. Endocannabinoid regulation of reward and reinforcement through interaction with dopamine and endogenous opioid signaling. Neuropsychopharmacology 43, 103–115 (2018).

doi: 10.1038/npp.2017.126 pubmed: 28653666

Haney, M. et al. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 38, 1557–1565 (2013).

doi: 10.1038/npp.2013.54 pubmed: 23443718 pmcid: 3682150

Haney, M. et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29, 158–170 (2004).

doi: 10.1038/sj.npp.1300310 pubmed: 14560320

Budney, A. J., Hughes, J. R., Moore, B. A. & Vandrey, R. Review of the validity and significance of cannabis withdrawal syndrome. Am. J. Psychiatry 161, 1967–1977 (2004).

doi: 10.1176/appi.ajp.161.11.1967 pubmed: 15514394

Zilm, D. H. & Sellers, E. M. The quantitative assessment of physical dependence on opiates. Drug Alcohol Depend. 3, 419–428 (1978).

doi: 10.1016/0376-8716(78)90014-5 pubmed: 720211

Slosky, L. M., Caron, M. G. & Barak, L. S. Biased allosteric modulators: new frontiers in GPCR drug discovery. Trends Pharmacol. Sci. 42, 283–299 (2021).

doi: 10.1016/j.tips.2020.12.005 pubmed: 33581873 pmcid: 9797227

Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–716 (2004).

doi: 10.1038/nrd1470 pubmed: 15286737

Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010).

doi: 10.1038/nrd3078 pubmed: 20168317

Kearney-Ramos, T. et al. The relationship between circulating endogenous cannabinoids and the effects of smoked cannabis. Cannabis Cannabinoid Res. https://doi.org/10.1089/can.2021.0185 (2022).

doi: 10.1089/can.2021.0185 pubmed: 35486827

Finlay, D. B. et al. Gα

doi: 10.1111/bph.13866 pubmed: 28516479 pmcid: 5513864

Wiley, J. L. et al. CB

doi: 10.1038/sj.bjp.0706157 pubmed: 15778743 pmcid: 1576140

Beyer, C. E. et al. Depression-like phenotype following chronic CB

doi: 10.1016/j.nbd.2010.03.020 pubmed: 20381618

Moreira, F. A., Grieb, M. & Lutz, B. Central side-effects of therapies based on CB

doi: 10.1016/j.beem.2008.09.003 pubmed: 19285266

Steiner, M. A. et al. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 33, 54–67 (2008).

doi: 10.1016/j.psyneuen.2007.09.008 pubmed: 17976922

Foltin, R. W., Fischman, M. W. & Byrne, M. F. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11, 1–14 (1988).

doi: 10.1016/S0195-6663(88)80017-5 pubmed: 3228283

Bellocchio, L. et al. Bimodal control of stimulated food intake by the endocannabinoid system. Nat. Neurosci. 13, 281–283 (2010).

doi: 10.1038/nn.2494 pubmed: 20139974

Kedzior, K. K. & Martin-Iverson, M. T. Chronic cannabis use is associated with attention-modulated reduction in prepulse inhibition of the startle reflex in healthy humans. J. Psychopharmacol. 20, 471–484 (2006).

doi: 10.1177/0269881105057516 pubmed: 16174673

Wilson, C. A. & Koenig, J. I. Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Eur. Neuropsychopharmacol. 24, 759–773 (2014).

doi: 10.1016/j.euroneuro.2013.11.008 pubmed: 24342774

Leggio, G. M. et al. In vivo evidence that constitutive activity of serotonin

doi: 10.1111/j.1471-4159.2009.06356.x pubmed: 19702657

Cooper, Z. D., Comer, S. D. & Haney, M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology 38, 1984–1992 (2013).

doi: 10.1038/npp.2013.97 pubmed: 23609132 pmcid: 3746706

Haney, M., Ward, A. S., Comer, S. D., Foltin, R. W. & Fischman, M. W. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141, 395–404 (1999).

doi: 10.1007/s002130050849 pubmed: 10090647

Haney, M. et al. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology 211, 233–244 (2010).

doi: 10.1007/s00213-010-1888-6 pubmed: 20521030 pmcid: 3323354